# A Study to Evaluate the Efficacy and Safety of Two Dose Strengths of Dalfampridine Extended Release Tablets.

> **NCT02271217** · PHASE3 · COMPLETED · sponsor: **Acorda Therapeutics** · enrollment: 377 (actual)

## Conditions studied

- Post-Ischemic Stroke

## Interventions

- **DRUG:** Placebo
- **DRUG:** dalfampridine-ER 7.5mg
- **DRUG:** dalfampridine-ER 10mg

## Key facts

- **NCT ID:** NCT02271217
- **Lead sponsor:** Acorda Therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-12
- **Primary completion:** 2016-09
- **Final completion:** 2016-10
- **Target enrollment:** 377 (ACTUAL)
- **Last updated:** 2018-06-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02271217

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02271217, "A Study to Evaluate the Efficacy and Safety of Two Dose Strengths of Dalfampridine Extended Release Tablets.". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT02271217. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*